Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,509 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Small cell lung cancer and progressive retinopathy.
Morita M, Fukuhara T, Takahashi H, Maemondo M. Morita M, et al. BMJ Case Rep. 2014 Nov 24;2014:bcr2014205888. doi: 10.1136/bcr-2014-205888. BMJ Case Rep. 2014. PMID: 25422332 Free PMC article.
Relapsed Myasthenia Gravis after Nivolumab Treatment.
Mitsune A, Yanagisawa S, Fukuhara T, Miyauchi E, Morita M, Ono M, Tojo Y, Ichinose M. Mitsune A, et al. Among authors: morita m. Intern Med. 2018 Jul 1;57(13):1893-1897. doi: 10.2169/internalmedicine.9153-17. Epub 2018 Feb 9. Intern Med. 2018. PMID: 29434145 Free PMC article.
PKM1 Confers Metabolic Advantages and Promotes Cell-Autonomous Tumor Cell Growth.
Morita M, Sato T, Nomura M, Sakamoto Y, Inoue Y, Tanaka R, Ito S, Kurosawa K, Yamaguchi K, Sugiura Y, Takizaki H, Yamashita Y, Katakura R, Sato I, Kawai M, Okada Y, Watanabe H, Kondoh G, Matsumoto S, Kishimoto A, Obata M, Matsumoto M, Fukuhara T, Motohashi H, Suematsu M, Komatsu M, Nakayama KI, Watanabe T, Soga T, Shima H, Maemondo M, Tanuma N. Morita M, et al. Cancer Cell. 2018 Mar 12;33(3):355-367.e7. doi: 10.1016/j.ccell.2018.02.004. Cancer Cell. 2018. PMID: 29533781 Free article.
Osimertinib in poor performance status patients with T790M-positive advanced non-small-cell lung cancer after progression of first- and second-generation EGFR-TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Ohizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: morita s, morita m. Int J Clin Oncol. 2022 Jan;27(1):112-120. doi: 10.1007/s10147-021-02043-2. Epub 2021 Oct 13. Int J Clin Oncol. 2022. PMID: 34643820 Free PMC article. Clinical Trial.
Correction to: Osimertinib in poor performance status patients with T790M‑positive advanced non‑small‑cell lung cancer after progression of first- and second‑generation EGFR‑TKI treatments (NEJ032B).
Tsubata Y, Watanabe K, Saito R, Nakamura A, Yoshioka H, Morita M, Honda R, Kanaji N, Oizumi S, Jingu D, Nakagawa T, Nakazawa K, Mouri A, Takeuchi S, Furuya N, Akazawa Y, Miura K, Ichihara E, Maemondo M, Morita S, Kobayashi K, Isobe T. Tsubata Y, et al. Among authors: morita s, morita m. Int J Clin Oncol. 2022 Apr;27(4):823-824. doi: 10.1007/s10147-022-02118-8. Int J Clin Oncol. 2022. PMID: 35257278 Free PMC article. No abstract available.
3,509 results